Who are in the management team of Gian Lifecare?

As of March 2019, the management team of Gian Lifecare includes Arun Kumar Gupta (Chairman & Managing Director), Rashika Agarwal (Non Executive Director), Umang Gupta and Abhiram Saran Agarwal (Additional Independent Directors), and Astha Chaturvedi and Vanshul Asnani (Company Secretaries). They oversee the company's operations and strategic direction.

As of March 2019, the management team of Gian Lifecare includes the following individuals:<BR><BR>1. Arun Kumar Gupta - Chairman & Managing Director<BR>2. Rashika Agarwal - Non Executive Director<BR>3. Umang Gupta - Additional Independent Director<BR>4. Abhiram Saran Agarwal - Additional Independent Director<BR>5. Astha Chaturvedi - Company Secretary<BR>6. Vanshul Asnani - Company Secretary<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What is the bonus history of the Gian Lifecare?

Gian Lifecare issued a bonus in a 6:5 ratio, with an ex-date of March 29, 2022, and a record date of March 30, 2022, making shareholders on record eligible for the bonus shares.

Gian Lifecare has a bonus history that includes a notable issue announced with a ratio of 6:5. This bonus was issued with an ex-date of March 29, 2022, and the record date was set for March 30, 2022. This means that shareholders on record as of the record date were eligible to receive the bonus shares. If you have any more questions about Gian Lifecare or its financial activities, feel free to ask!

Has Gian Lifecare declared dividend?

No Dividend History Available

Who are the peers of the Gian Lifecare?

Gian Lifecare's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online. Poly Medicure has the highest 1-year return at 24.45%, while Gian Lifecare's return is -28.14%.

Peers: The peers of Gian Lifecare are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab, and the rest have Below Average management risk. Growth is Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Dhanvantri Jeev., Average growth is found at Gian Lifecare, Poly Medicure, Indegene, and the rest have Does not qualify growth. Excellent capital structure is noted at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Good capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.45%, while the peer with the lowest is Vanta Bioscience at -54.78%. Gian Lifecare's own 1-year return is -28.14%, which is higher than Vanta Bioscience's but lower than Poly Medicure's. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online.

What is the technical trend for Gian Lifecare?

As of June 4, 2025, Gian Lifecare's trend is bearish with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals from the MACD and KST.

As of 4 June 2025, the technical trend for Gian Lifecare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but the monthly MACD is bearish, suggesting a divergence in momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are also bearish, indicating a downward trend in the short term. The KST shows a mildly bullish signal on the weekly chart, but is bearish monthly, which adds to the mixed signals. Overall, the bearish trend is supported by the recent price action and the longer-term performance, with the stock down 21.95% over the past year compared to a 7.50% increase in the Sensex.

What does Gian Lifecare do?

Gian Lifecare Ltd is a healthcare services company specializing in diagnostic services, with recent net sales of 20 Cr and a net profit of 1 Cr as of September 2024. It has a market cap of INR 15 Cr and a P/E ratio of 4.00.

Overview: <BR>Gian Lifecare Ltd operates in the healthcare services industry, specifically focusing on diagnostic services.<BR><BR>History: <BR>The company was incorporated in 2018 and acquired the business of M/s Gian Pathology & X-Ray in March 2019. The latest quarterly results reported net sales and profit for September 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 20 Cr (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Sep 2024) <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 4.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 19.96% <BR>Price to Book: 0.79 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Gian Lifecare?

The top shareholders of Gian Lifecare include Arun Kumar Gupta with 28.89%, individual investors holding 56.62%, and Shield Multistate Cooperative Credit with 6.49%. There are no mutual funds or foreign institutional investors involved, and 62.27% of promoter holdings are pledged.

The top shareholders of Gian Lifecare include Arun Kumar Gupta, who is the promoter with the highest holding at 28.89%. The company has a significant portion of its shares held by individual investors, totaling 56.62%. Additionally, the highest public shareholder is Shield Multistate Cooperative Credit, which holds 6.49% of the shares. It's important to note that there are no mutual funds or foreign institutional investors holding shares in the company, and the pledged promoter holdings stand at 62.2704%.

How big is Gian Lifecare?

As of 24th July, Gian Lifecare Ltd has a market capitalization of 16.00 Cr, with recent net sales of 10.12 Cr and a net profit of 2.69 Cr. The company has shareholder's funds of 19.28 Cr and total assets of 32.64 Cr.

As of 24th July, Gian Lifecare Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Gian Lifecare reported Net Sales of 10.12 Cr and a Net Profit of 2.69 Cr.<BR><BR>For the latest annual period ending March 2024, the company has Shareholder's Funds amounting to 19.28 Cr and Total Assets of 32.64 Cr.

When is the next results date for Gian Lifecare?

The next results date for Gian Lifecare is 14 August 2025.

The next results date for Gian Lifecare is scheduled for 14 August 2025.

Are Gian Lifecare latest results good or bad?

Gian Lifecare's latest results show a 108.33% increase in net profit but a 21.62% decline in net sales, indicating mixed performance. The decreased performance score and a 'Strong Sell' recommendation suggest caution for investors.

Gian Lifecare's latest financial results indicate a mixed performance. While the company reported a significant increase in consolidated net profit of 108.33% compared to the previous quarter, net sales saw a decline of 21.62%. This flat overall performance suggests that while profitability has improved, the drop in sales raises concerns about the company's growth trajectory.<BR><BR>Additionally, the performance score has decreased from 6 to 0, which reflects a notable shift in its financial standing and may indicate operational challenges. The stock call of 'Strong Sell' from MarketsMOJO further suggests a cautious outlook on the company's future performance.<BR><BR>In summary, while there are some positive signs in terms of profit, the overall results are concerning, and investors should approach with caution.

Should I buy, sell or hold Gian Lifecare?

How has been the historical performance of Gian Lifecare?

Gian Lifecare has experienced significant declines in net sales and profitability from Mar'22 to Mar'25, with net sales dropping from 15.93 Cr to 6.63 Cr and profit after tax turning negative at -0.04 Cr. Despite these challenges, total assets and liabilities increased, indicating a growing financial base.

Answer:<BR>The historical performance of Gian Lifecare has shown significant fluctuations over the years, particularly in its net sales and profitability metrics.<BR><BR>Breakdown:<BR>Gian Lifecare's net sales decreased from 15.93 Cr in Mar'22 to 6.63 Cr in Mar'25, reflecting a downward trend over the years, with a notable drop from 13.12 Cr in Mar'24. Total operating income followed a similar pattern, declining from 15.93 Cr in Mar'22 to 6.63 Cr in Mar'25. The company's total expenditure also decreased, from 9.90 Cr in Mar'22 to 5.72 Cr in Mar'25. Operating profit (PBDIT) saw a significant decline, dropping from 6.54 Cr in Mar'22 to 1.17 Cr in Mar'25, with a corresponding decrease in profit before tax from 5.85 Cr in Mar'22 to just 0.04 Cr in Mar'25. Consequently, profit after tax turned negative in Mar'25 at -0.04 Cr, down from 4.15 Cr in Mar'24 and 4.37 Cr in Mar'22. The company's earnings per share (EPS) also reflected this decline, falling to -0.04 in Mar'25 from 4.01 in Mar'24. On the balance sheet, total liabilities increased from 23.06 Cr in Mar'22 to 32.64 Cr in Mar'24, while total assets rose from 23.06 Cr in Mar'22 to 32.64 Cr in Mar'24, indicating a growing financial base despite the declining profitability. Cash flow from operating activities remained at 0.00 Cr in Mar'24, with closing cash and cash equivalents stable at 5.00 Cr. Overall, Gian Lifecare's performance has been marked by declining revenues and profits, alongside an increase in liabilities.

Is Gian Lifecare overvalued or undervalued?

As of September 4, 2025, Gian Lifecare is considered overvalued with a PE ratio of -14.79 and a year-to-date return of -23.94%, significantly underperforming compared to its peers and the overall market.

As of 4 September 2025, Gian Lifecare's valuation grade has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its PE ratio of -14.79, a Price to Book Value of 0.77, and an EV to EBITDA of 13.68. These metrics suggest that the stock is not only trading at a high valuation relative to its earnings but also reflects a concerning financial position with negative earnings.<BR><BR>In comparison to its peers, Gian Lifecare's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 93.55, while Apollo Hospitals maintains a PE of 72.11, both indicating a more robust earnings outlook. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -23.94%, contrasting sharply with the Sensex's positive return of 3.30% over the same period. This further reinforces the notion that Gian Lifecare is currently overvalued in the healthcare services sector.

Which are the latest news on Gian Lifecare?

Why is Gian Lifecare falling/rising?

As of 14-Dec, Gian Lifecare Ltd's stock price is at Rs. 8.99, reflecting a 1.32% decrease and a 29.21% decline over the past month. The stock is underperforming the market, has reached a 52-week low, and shows waning investor interest, indicating significant challenges ahead.

As of 14-Dec, Gian Lifecare Ltd's stock price is falling, currently at Rs. 8.99, which reflects a decrease of Rs. 0.12 or 1.32%. The stock has been on a downward trend, having lost 13.64% over the past week and 29.21% over the past month. This decline is further highlighted by the fact that the stock has reached a new 52-week low of Rs. 8.66 today. <BR><BR>Additionally, the stock has been underperforming compared to the broader market, as evidenced by its performance relative to the Sensex, which has gained 0.95% over the past month while Gian Lifecare has significantly declined. The stock has also been trading below its moving averages across various time frames, indicating a persistent bearish trend. <BR><BR>Investor participation appears to be waning, with a notable drop in delivery volume, which fell by 92.23% against the 5-day average. This lack of investor interest, combined with the consecutive five-day decline, suggests that there are significant challenges facing the company, contributing to the ongoing decrease in its stock price.